Clinical Trial Update: Low Dose Nivolumab With Chemotherapy vs Standard Chemotherapy as First-Line Treatment in Advanced or Metastatic NSCLC [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating low-dose nivolumab in combination with chemotherapy versus standard chemotherapy as first-line treatment for advanced or metastatic non…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• nivolumab (nivolumab)

Snippet

Sponsor: Dr Arvindran A/L Alaga | Conditions: NSCLC (Non-small Cell Lung Carcinoma), First Line Therapy | Phase 3 | Status: RECRUITING